BIOMARKER:

Chr del(17)(p13.1)

Chr del(17)(p13.1) Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: B - Late Trials
Chr del(17)(p13.1) Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia CLL	rituximab + ibrutinib Sensitive: B - Late Trials
Chr del(17)(p13.1) Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia CLL	alemtuzumab Sensitive: C3 – Early Trials
Chr del(17)(p13.1) Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia CLL	obinutuzumab Sensitive: C3 – Early Trials
Chr del(17)(p13.1) Chr del(17)(p13.1)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	acalabrutinib Sensitive: C3 – Early Trials
Chr del(17)(p13.1) Chr del(17)(p13.1)	Chronic Lymphocytic Leukemia CLL	acalabrutinib Sensitive: C3 – Early Trials

Associations